➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Harvard Business School
Boehringer Ingelheim
Dow
Moodys

Last Updated: June 3, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Triciribine


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Triciribine?

Triciribine is an investigational drug.

There have been 5 clinical trials for Triciribine. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2014.

The most common disease conditions in clinical trials are Leukemia, Neoplasms, and Neoplasm Metastasis. The leading clinical trial sponsors are Prescient Therapeutics, Ltd., VioQuest Pharmaceuticals, and National Cancer Institute (NCI).

There is one US patent protecting this investigational drug and eight international patents.

Recent Clinical Trials for Triciribine
TitleSponsorPhase
A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute LeukemiaPrescient Therapeutics, Ltd.Phase 1/Phase 2
PTX-200 and Carboplatin in Ovarian CancerPrescient Therapeutics, Ltd.Phase 1/Phase 2
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast CancerNational Cancer Institute (NCI)Phase 1/Phase 2

See all Triciribine clinical trials

Clinical Trial Summary for Triciribine

Top disease conditions for Triciribine
Top clinical trial sponsors for Triciribine

See all Triciribine clinical trials

US Patents for Triciribine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Triciribine   Start Trial Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)   Start Trial
Triciribine   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Triciribine   Start Trial Use of inhibitors of Bruton'S tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Triciribine   Start Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
Triciribine   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
Triciribine   Start Trial Inhibition of hypoxia-inducible factor activity with carica papaya extracts The Regents of the University of California (Oakland, CA) Universiti Putra Malaysia (Selangor Darul Ehsan, MY)   Start Trial
Triciribine   Start Trial Compositions and methods including celecoxib and plumbagin relating to treatment of cancer The Penn State Research Foundation (University Park, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Triciribine

Drugname Country Document Number Estimated Expiration Related US Patent
Triciribine Australia 2006213610 2025-02-10   Start Trial
Triciribine Canada 2596845 2025-02-10   Start Trial
Triciribine Denmark 1851340 2025-02-10   Start Trial
Triciribine European Patent Office 1851340 2025-02-10   Start Trial
Triciribine Hong Kong 1115165 2025-02-10   Start Trial
Triciribine Japan 2008535474 2025-02-10   Start Trial
Triciribine Japan 5031587 2025-02-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.